On August 5th, Glon Hui reported that Huaren Pharmaceutical (300110.SZ) recently announced that its wholly-owned subsidiary, Anhui Hengxing Pharmaceutical Co., Ltd. (referred to as 'Anhui Hengxing Pharmaceutical' below), has received the 'Ketamine Hydrochloride Injection' Drug Registration Certificate issued and approved by the State Drug Administration of China.
'Ketamine Hydrochloride Injection' is suitable for peripheral arterial disease (intermittent claudication or rest pain) and inner ear circulation disorders, and is a National Medical Insurance Class B product.